InvestSMART

ResMed Inc. (ASX: RMD) - Announcements

Current share price for RMD : $27.430 0.11 (0.40%)+

ASX company news and announcements for ResMed Inc. (RMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ResMed Inc. (RMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ResMed Inc. (RMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ResMed Inc. (RMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$16,293 Record Financial Results for Quarter Ended December 31,2013 24 Jan 2014 10:02AM $5.000 $27.430 risen by 448.60%
$16,293 New Credit Facility - Form 8-K 6 Nov 2013 10:57AM $5.280 $27.430 risen by 419.51%
$16,293 Record Financial Results for Quarter Ended September 30,2013 25 Oct 2013 9:18AM $5.410 $27.430 risen by 407.02%
$16,293 Record Financial Results For 4Q13 & Fiscal Year-End 2 Aug 2013 9:15AM $5.450 $27.430 risen by 403.30%
$16,293 ResMed Succeeds in Patent Fight Against APEX 19 Jul 2013 9:45AM $4.880 $27.430 risen by 462.09%
$16,293 ResMed and University of Sydney Partnership Agreement 14 May 2013 8:58AM $5.090 $27.430 risen by 438.90%
$16,293 Record Financial Results for Q/E & 9 Months Mar 31, 2013 26 Apr 2013 8:44AM $4.460 $27.430 risen by 515.02%
$16,293 ResMed files legal action to Enforce Patents 2 Apr 2013 10:01AM $4.390 $27.430 risen by 524.83%
$16,293 ResMed Appoints CEO & COO 27 Feb 2013 1:59PM $4.240 $27.430 risen by 546.93%
$16,293 RESMED APPOINTS MICHAEL FARRELL AS CHIEF EXECUTIVE OFFICER 21 Feb 2013 8:59AM $4.180 $27.430 risen by 556.22%
$16,293 Record Financial Results for Q/E & 6 Months Dec 31, 2012 25 Jan 2013 9:08AM $4.580 $27.430 risen by 498.91%
$16,293 Form 10Q for QTR ended September 30, 2012 1 Nov 2012 9:18AM $3.820 $27.430 risen by 618.06%
$16,293 Record Financial Results for Quarter Ended September 30,2012 26 Oct 2012 9:04AM $3.990 $27.430 risen by 587.47%
$16,293 Record Financial Results for 4Q12 & Fiscal Year-End 3 Aug 2012 8:55AM $3.300 $27.430 risen by 731.21%
$16,293 RESMED INITIATES DIVIDEND PLAN AND CEO UPDATE 18 May 2012 9:41AM $3.260 $27.430 risen by 741.41%
$16,293 Record Financial Results for Quarter Ended March 31, 2012 27 Apr 2012 8:30AM $3.260 $27.430 risen by 741.41%
$16,293 Amendment to Credit Agreement 27 Jan 2012 9:31AM $2.730 $27.430 risen by 904.76%
$16,293 Record Financial Results for the Q/E December 31, 2011 27 Jan 2012 9:30AM $2.730 $27.430 risen by 904.76%
$16,293 Financial Results For The Quarter Ended Sep 30, 2011 25 Oct 2011 8:50AM $2.610 $27.430 risen by 950.96%
$16,293 Appendix 4E and Form 10 k 18 Aug 2011 9:00AM $2.750 $27.430 risen by 897.45%
$16,293 Record Results for the Quarter and 12 months June 30, 2011 5 Aug 2011 9:16AM $2.660 $27.430 risen by 931.20%
$16,293 RESMED ANNOUNCES ACQUISITION OF BIANCAMED 7 Jul 2011 9:17AM $2.860 $27.430 risen by 859.09%
$16,293 Record Financial Results for Qtr and 9 months March 31, 2011 29 Apr 2011 9:16AM $2.950 $27.430 risen by 829.83%
$16,293 RMD announces the release of it`s new S9VPAP series 12 Apr 2011 9:40AM $3.000 $27.430 risen by 814.33%
$16,293 Credit Agreement 15 Feb 2011 10:08AM $3.240 $27.430 risen by 746.60%

626 - 650 of 703 results

Page 26 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.